Glucagon-Like Peptides (Enteroglucagon)

Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.

Also Known As:

Networked: 93 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kissow, Hannelouise: 1 article (06/2015)
2.	Kaunitz, J D: 1 article (05/2013)
3.	Kaji, I: 1 article (05/2013)
4.	Akiba, Y: 1 article (05/2013)
5.	Watts, Gerald F: 1 article (02/2013)
6.	Chan, Dick C: 1 article (02/2013)
7.	Guz, Yelena: 1 article (07/2012)
8.	Charron, Maureen J: 1 article (07/2012)
9.	Kedees, Mamdouh H: 1 article (07/2012)
10.	Grigoryan, Marine: 1 article (07/2012)

Related Diseases

1.	Celiac Disease (Celiac Sprue) 01/01/1984 - "Evidently determination of plasma enteroglucagon concentration is effective in diagnosing celiac disease, thereby improving the selection of patients for small-intestinal biopsy." 04/01/1985 - "To study whether or not plasma enteroglucagon reflects changes of the small intestinal mucosa during different phases of celiac disease, we studied fasting and postprandial concentrations of plasma enteroglucagon, as well as small intestinal mucosa morphology, in children with celiac disease and in a reference group of children without gastrointestinal disorders. " 10/15/1985 - "[Enteroglucagon cells in the jejunal mucosa in celiac disease, before, during and after diet treatment. " 04/01/1985 - "These findings suggest that plasma enteroglucagon levels, particularly after a mixed meal, are correlated with the small intestinal mucosal morphology in childhood celiac disease. " 04/01/1985 - "Plasma enteroglucagon in the control of childhood celiac disease."
2.	Necrolytic Migratory Erythema 05/01/1989 - "The findings demonstrate that necrolytic migratory erythema is not an exclusively paraneoplastic phenomenon and that it can occur in association with excess production of enteroglucagon by the intestinal mucosa." 05/01/1989 - "Necrolytic migratory erythema with elevated plasma enteroglucagon in celiac disease." 05/01/1989 - "Treatment with gluten-free diet not only resulted in resolution of malabsorption and improvement in small intestinal histology but was paralleled by disappearance of necrolytic migratory erythema, normalization of plasma glucagon levels, and marked reduction in the number of enteroglucagon-producing crypt cells (0.2/mm2 mucosa). "
3.	Prolactinoma (Prolactinomas) 01/01/1983 - "Enteroglucagon and GIP after oral glucose in patients with prolactinoma and acromegaly." 01/01/1983 - "We have performed oral glucose tolerance tests (OGTT) in nine patients with prolactinomas, eight patients with active acromegaly, five patients with acromegaly in remission and nine normal controls, and measured blood glucose, plasma insulin, pancreatic glucagon, enteroglucagon, gastric inhibitory polypeptide (GIP) and GH during the test. "
4.	Acromegaly 01/01/1983 - "Of particular interest was the finding that enteroglucagon, a putative gut growth factor, was low in active acromegaly when compared with acromegaly in remission, but similar to normal in the rest of the patients." 01/01/1983 - "Enteroglucagon and GIP after oral glucose in patients with prolactinoma and acromegaly." 01/01/1983 - "We have performed oral glucose tolerance tests (OGTT) in nine patients with prolactinomas, eight patients with active acromegaly, five patients with acromegaly in remission and nine normal controls, and measured blood glucose, plasma insulin, pancreatic glucagon, enteroglucagon, gastric inhibitory polypeptide (GIP) and GH during the test. "
5.	Hyperplasia 07/01/2012 - "We sought to determine whether the increased level of the glucagon-like peptides is due to L cell hyperplasia. " 05/01/1997 - "These findings suggest that pancreatic hyperplasia observed after PSBR is attenuated by ageing, probably due to an insufficient increase in plasma enteroglucagon levels." 11/01/1994 - "These findings demonstrated that plasma CCK was not the major trophic factor operating in the pancreas after PSBR, and showed that enteroglucagon plays an important role in the pancreatic hyperplasia that occurs after PSBR." 11/01/1994 - "Enteroglucagon, but not CCK, plays an important role in pancreatic hyperplasia after proximal small bowel resection." 01/01/1990 - "However, we have shown that there are experimental conditions (germ-free rats after conventionalisation; jejunal self-filling blind loops) in which intestinal hyperplasia does not correspond to an increase in the concentrations of enteroglucagon in plasma or intestinal mucosa. "

Related Drugs and Biologics

1.	Glucagon (Glukagon)
2.	Insulin (Novolin)
3.	Gastric Inhibitory Polypeptide (Glucose Dependent Insulinotropic Peptide)
4.	Glucose (Dextrose)
5.	Blood Glucose (Blood Sugar)
6.	Hormones
7.	Cholecystokinin (Pancreozymin)
8.	C-Peptide
9.	Gastrins
10.	Pancreatic Polypeptide (Pancreatic Polypeptide (PP))

Related Therapies and Procedures

1.	Gastric Bypass (Roux-en-Y Gastric Bypass)
2.	Enteral Nutrition (Feeding, Tube)
3.	Gastroplasty (Vertical-Banded Gastroplasty)